RxDoctor Payments Data

Stacie Setchell

Optometrist · Morrison, ILNPI 1528220670

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,500 of the $15,588 with a category attached, or 93.0%. Glaukos Corporation accounts for 94.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $8,548 and has fallen 97.4% since, to $225 in 2025. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,588in general payments, 2019–2025

Across 64 payments — averaging $243.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$15K
  • Coopervision Inc.$183
  • Alcon$155
  • Amgen$119
  • Harrow Eye, LLC$96
  • Tarsus Pharmaceuticals, Inc.$76
  • plus $310 from 9 others

What the payments were for

  • Consulting fees$14,50093%
  • Travel & lodging$1831%
  • Food & beverage$9056%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,588 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$52,780
Medicare patients
329
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine63$89,567
CequaCyclosporine31$39,771
Cyclosporine19$11,186
LumiganBimatoprost13$9,681
Latanoprost108$1,072
Prednisolone Acetate27$992
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$19$99,24876 claims
Sun Pharmaceutical Industries Inc.Cequa$60$39,77131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Morrison

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →